-
Experienced Technology, Commercial, and Intellectual Property Attorney
For over 20 years, Mark has advised public and private companies, investors, and institutions on a variety of strategic technology, commercial, and intellectual property transactions, including strategic alliances, collaborations, licenses, joint ventures, and global supply chain, distribution, and commercialization structures.
-
A Focus on the Full Spectrum of Life Sciences Industries
His practice focuses on the pharmaceutical, biotechnology, diagnostic, digital health, and medical device industries.
-
Commitment to Clients at All Stages of the Business Life Cycle
Mark represents clients across the full spectrum of organizational development, from the largest global pharmaceutical companies to emerging biotechnology start-up companies.
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
Mark specializes in working with his clients on the most complex strategic alliances and collaborations for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. In 2022, Mark was recognized as a "Life Science Star" in the intellectual property section of LMG Life Sciences.
Prior to joining the firm, Mark was an IP transactions partner in the Boston office of Ropes & Gray. Earlier in his career, he was also senior licensing counsel for Wyeth Pharmaceuticals. Before attending law school, Mark served as a cavalry officer and scout platoon leader in the United States Army.
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
Mark specializes in working with his clients on the most complex strategic alliances and collaborations for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements. In 2022, Mark was recognized as a "Life Science Star" in the intellectual property section of LMG Life Sciences.
Prior to joining the firm, Mark was an IP transactions partner in the Boston office of Ropes & Gray. Earlier in his career, he was also senior licensing counsel for Wyeth Pharmaceuticals. Before attending law school, Mark served as a cavalry officer and scout platoon leader in the United States Army.
- J.D., Harvard Law School, 2000
Magna Cum Laude
- B.S., Electrical Engineering, United States Military Academy at West Point, 1994
Distinguished Cadet, Phi Kappa Phi, Eta Kappa Nu
- Honored as a BTI Client Service All Star (2019)
- Recognized in Legal 500 (2013-2018)
- Named as a BTI Client Service All Stars MVP (2016)
- Recognized as lead outside counsel on the Pfizer-Merck KGaA anti-PD-L1 antibodies collaboration, a transaction that was honored as the 2015 “Deal of Distinction” in the Life Sciences category by the Licensing Executives Society
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
- J.D., Harvard Law School, 2000
Magna Cum Laude
- B.S., Electrical Engineering, United States Military Academy at West Point, 1994
Distinguished Cadet, Phi Kappa Phi, Eta Kappa Nu
- Honored as a BTI Client Service All Star (2019)
- Recognized in Legal 500 (2013-2018)
- Named as a BTI Client Service All Stars MVP (2016)
- Recognized as lead outside counsel on the Pfizer-Merck KGaA anti-PD-L1 antibodies collaboration, a transaction that was honored as the 2015 “Deal of Distinction” in the Life Sciences category by the Licensing Executives Society
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
Illustrative Representations
- G1 Therapeutics in global partnering arrangements for its two lead product candidates, including strategic licenses with Genor and Simcere, and U.S. co-promotion agreement with Boehringer Ingelheim*
- EQRx in multiple strategic global and regional license and collaboration transactions in support of its Remaking MedicineTM mission*
- AMAG Pharmaceuticals in its license and collaboration with Palatin Technologies, Inc. for RekyndaTM (bremelanotide)*
- Strata Oncology in its co-development and collaboration agreement with Arcus Biosciences*
- Alexion Pharmaceuticals in multiple license and collaboration transactions, including its collaborations with Eidos Therapeutics and Affibody AB, and its option agreement with Stealth Biopharmaceuticals*
- Verastem in its licensing agreement with Infinity Pharmaceuticals*
- Pfizer in multiple early and late-stage collaborations, including global collaborations with Merck KGaA (PD-L1 antibodies), MedGenesis Therapeutix (GDNF), Eli Lilly (MAb antinerve grow factors), and MSD International GmbH (SGLT-2 inhibitors)*
- AstraZeneca in its global partnership agreement with Eolas Therapeutics (Orexin-1 Receptor Antagonist)*
- Genzyme in its collaboration with Alnylam Pharmaceuticals (rare disease siRNA drug candidates)*
- Ironwood Pharmaceuticals in its late-stage license with AstraZeneca for Zurampic®*
- Partners Healthcare in its licensing and implementation of the Epic Electronic Health Record platform
- Immunogen, Astellas, Biogen, Foundation Medicine, Catabasis, Waters, and other leading pharmaceutical, diagnostic, and medical technology companies in multiple collaboration, co-promotion, manufacturing, distribution, and commercialization relationships*
- Development and implementation of licensing and collaboration best practices programs for multiple leading biopharmaceutical, medical device, and medical technology companies*
* Denotes client experience from another firm prior to joining Wilson Sonsini in 2021.
Illustrative Representations
- G1 Therapeutics in global partnering arrangements for its two lead product candidates, including strategic licenses with Genor and Simcere, and U.S. co-promotion agreement with Boehringer Ingelheim*
- EQRx in multiple strategic global and regional license and collaboration transactions in support of its Remaking MedicineTM mission*
- AMAG Pharmaceuticals in its license and collaboration with Palatin Technologies, Inc. for RekyndaTM (bremelanotide)*
- Strata Oncology in its co-development and collaboration agreement with Arcus Biosciences*
- Alexion Pharmaceuticals in multiple license and collaboration transactions, including its collaborations with Eidos Therapeutics and Affibody AB, and its option agreement with Stealth Biopharmaceuticals*
- Verastem in its licensing agreement with Infinity Pharmaceuticals*
- Pfizer in multiple early and late-stage collaborations, including global collaborations with Merck KGaA (PD-L1 antibodies), MedGenesis Therapeutix (GDNF), Eli Lilly (MAb antinerve grow factors), and MSD International GmbH (SGLT-2 inhibitors)*
- AstraZeneca in its global partnership agreement with Eolas Therapeutics (Orexin-1 Receptor Antagonist)*
- Genzyme in its collaboration with Alnylam Pharmaceuticals (rare disease siRNA drug candidates)*
- Ironwood Pharmaceuticals in its late-stage license with AstraZeneca for Zurampic®*
- Partners Healthcare in its licensing and implementation of the Epic Electronic Health Record platform
- Immunogen, Astellas, Biogen, Foundation Medicine, Catabasis, Waters, and other leading pharmaceutical, diagnostic, and medical technology companies in multiple collaboration, co-promotion, manufacturing, distribution, and commercialization relationships*
- Development and implementation of licensing and collaboration best practices programs for multiple leading biopharmaceutical, medical device, and medical technology companies*
* Denotes client experience from another firm prior to joining Wilson Sonsini in 2021.
Traditional TCEs targeting “cold” tumors have limited efficacy due to poor T cell quality and exhaustion. Marengo’s proprietary first-in-class TriSTAR TCEs have the potential to overcome these limitations, redirecting a new and expanded pool of highly activated memory Vβ T cells to the tumor. The teams will focus on exploring potential in cold tumors, which typically fail to trigger a strong immune response when treated with TCEs.
Under the terms of the agreement, Ipsen will assume responsibility for all activities following development candidate nomination. Marengo will receive an upfront payment and potential payments up to a total of $1.2 billion if all milestones are met, in addition to tiered sales royalty payments.
The Wilson Sonsini team advising Marengo Therapeutics on the transaction included Mark Bellomy, Chris McAndrew, Lauren Wardle, and Angel Wang.
- Privacy Policy
- Terms of Use
- Accessibility